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October 2018 Gene-Environment Interactions and Esophageal Adenocarcinoma 1599Barrett’s Esophagus Gene Study, and the UK Stomach and Oesophageal Cancer Study. We
analyzed 993,501 SNPs in DNA samples of all study subjects. We used standard case–control
logistic regression to test for gene-environment interactions.RESULTS: For EA, rs13429103 at chromosome 2p25.1, near the RNF144A-LOC339788 gene, showed a
borderline significant interaction with smoking status (P ¼ 2.18310-7). Ever smoking was
associated with an almost 12-fold increase in risk of EA among individuals with rs13429103-AA
genotype (odds ratio[11.82; 95% CI, 4.03–34.67). Three SNPs (rs12465911, rs2341926,
rs13396805) at chromosome 2q23.3, near the RND3-RBM43 gene, interacted with GERD
symptoms (P[ 1.70310-7, P[ 1.83310-7, and P[ 3.58310-7, respectively) to affect risk of EA.
For BE, rs491603 at chromosome 1p34.3, near the EIF2C3 gene, and rs11631094 at chromo-
some 15q14, at the SLC12A6 gene, interacted with BMI (P [ 4.44310-7) and pack-years of
smoking history (P [ 2.82310-7), respectively.CONCLUSION: The associations of BMI, smoking, and GERD symptoms with risks of EA and BE appear to
vary with SNPs at chromosomes 1, 2, and 15. Validation of these suggestive interactions
is warranted.Keywords: Esophageal Neoplasm; Genetic Variants; Risk Factors; Esophagus.Over the past 4 decades, the incidence ofesophageal adenocarcinoma (EA) has increased
markedly in many Western populations. Among white
men in the United States the incidence has increased
almost 10-fold,1 and rates continue to rise by 2% per
year.2 EA is a highly fatal cancer with a median overall
survival of <1 year following diagnosis.3 EAs typically
arise on a background of a premalignant change in the
lining of the esophagus known as Barrett’s esophagus
(BE). Thus, proposals to prevent EA-associated morbidity
and mortality have suggested focusing on identifying
patients with BE and enrolling them in endoscopic sur-
veillance programs, or on identifying and modifying
risk factors for neoplastic progression.4–6
Epidemiologic studies have identified frequent or
persistent symptoms of gastroesophageal reflux disease
(GERD),7,8 obesity,9 and smoking10,11 as the principal
factors associated with increased risks of EA and BE.
These 3 factors together comprise almost 80% of the
attributable burden of EA.12,13 Genetic factors also
influence risk of EA and BE. Recent genome-wide asso-
ciation studies (GWAS) and post-GWAS studies have
identified more than 20 loci significantly associated with
risks of EA and BE14; however, these variants seem to
explain only a limited proportion of the heritability of
these diseases (estimated to be 25% for EA and 35% for
BE).15 It is possible that environmental risk factors for
EA and BE may interact with multiple genes through
various biological pathways to contribute to disease
susceptibility. Given the strength of associations with
known risk factors for EA and BE (especially when
compared with most other cancers), and potentially
shared biological pathways (eg, inflammation) underly-
ing these risk factors,16 identifying gene-environment
interactions may be more plausible in the setting of EA
and BE. These gene-environment interactions may
account for some of the missing heritability of EA andBE.15 However, previous efforts to identify gene-
environment interactions for EA and BE have predomi-
nantly been candidate based and have involved only small
numbers of single nucleotide polymorphisms (SNPs).17–19
With the aim of identifying SNPs that may modify the
associations of body mass index (BMI), smoking, and
GERD symptoms with risks of EA and BE, we used pooled
questionnaire and genetic data from several studies to
conduct a large scale genome-wide gene-environment
interaction study of EA and BE.Methods
Study Population
We obtained data from 1512 EA patients, 2413 BE
patients, and 2185 control subjects of European ancestry
from 14 epidemiologic studies conducted in Western
Europe, Australia, and North America participating in
the International Barrett’s and Esophageal Adenocarci-
noma Consortium (http://beacon.tlvnet.net/) GWAS.
The design of the Barrett’s and Esophageal Adenocar-
cinoma Consortium GWAS has been described in detail
previously.20 Histological confirmation of EA and BE
was carried out for all the participating studies. The
pooled dataset also included an additional 1,003 EA
patients and 882 BE patients from the United Kingdom
Stomach and Oesophageal Cancer Study and the UK
Barrett’s Esophagus Gene Study, respectively.20 The EA
patients in the UK Stomach and Oesophageal Cancer
Study had International Classification of Diseases cod-
ing of malignant neoplasm of the esophagus (C15) and
pathological diagnosis of adenocarcinoma (M8140-
8575). The BE patients were identified at endoscopy
with confirmed histopathological diagnosis of intestinal
metaplasia in the UK Barrett’s Esophagus Gene Study.
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tional review board approval and all participants gave
informed consent.SNP Genotyping
Genotyping of buffy coat or whole blood DNA from all
participants was conducted using the Illumina Omni1M
Quad platform (San Diego, CA), in accordance with
standard quality-control procedures.21 For quality con-
trol, genotyped SNPs were excluded based on call rate
<95%, Hardy-Weinberg Equilibrium P value over con-
trols of <10–4, or minor allele frequency (MAF) 2%.
After quality assurance and quality control, 993,501
SNPs were used for the current analysis. The analysis
was restricted to the subset of ethnically homogenous
individuals of European ancestry (confirmed in GWAS
samples using principal components analysis).20Environmental (“Exposure”) Variables
Individual-level exposure data for each study
participant were harmonized and merged into a single
deidentified dataset. The data were checked for
consistency and completeness and any apparent
inconsistencies were followed up with individual study
investigators. Depending on the study, data from
self-reported written questionnaires or in-person
interviews were obtained at or near the time of can-
cer diagnosis for EA patients, at or near the time of BE
diagnosis for BE patients, and at the time of recruitment
for control subjects. BMI was calculated as weight
divided by square of height (kg/m2). For the analysis
we selected the weight from each participant that likely
reflected usual adult weight (before, for example, any
disease-related weight loss). For tobacco smoking, the
exposure variables were smoking status (ever vs never)
and total cigarette smoking exposure among ever
smokers (pack-years of smoking exposure). Ever ciga-
rette smoking was defined as either low threshold
exposure (100 cigarettes over their whole life) or by
asking whether they had ever smoked regularly. Pack-
years of smoking exposure was derived by dividing
the average number of cigarettes smoked daily by 20
and multiplying by the total number of years smoked.
GERD symptoms were defined as the presence of
heartburn (ie, a burning or aching pain behind the
sternum) or acid reflux (ie, a sour taste from acid,
bile, or other stomach contents rising up into the
mouth). For analysis, we used the highest reported
frequency for either GERD symptom. Participants
were then categorized as recurrent vs not recurrent
based on a frequency of weekly or greater GERD
symptoms for “recurrent.”7 A total of 425 participants
with missing values for all 3 covariates (BMI, smoking
history, and history of GERD symptoms) were excluded
from the analysis.Statistical Analysis
We used standard case-control logistic regression to
test for gene-environment interactions. SNP genotypes
were treated as continuous variables and coded as 0, 1,
or 2 copies of the minor allele. Exposure variables were
either continuous (BMI and pack-years of smoking
exposure) or dichotomous (smoking status and GERD
symptoms). We modeled the gene-environment interac-
tion by the product of the SNP genotype and the expo-
sure variable, adjusting for age, sex, the first 4 principal
components to control for possible population stratifi-
cation, and the main terms of the SNP and the exposure
variable. We used model-robust standard errors as sug-
gested in Voorman et al22 to avoid inflated test statistics
that can arise due to underestimation of variability in
gene-environment GWAS. For SNPs from each of the top
gene-environment interaction hits (ie, main text, P value
for interaction <5.0  10–7) (Supplemental Material,
P value for interaction <1.0  10–6) we also performed
stratified analyses by genotype to examine the modified
association of the known risk factor for EA or BE within
the specific genotypes. Analyses were conducted using
R software version 3.4.3. (R Foundation for Statistical
Computing, Vienna, Austria), the GWASTools package,23
and Stata 13.0 (StataCorp LP, College Station, TX).
Results
The final study sample included 2284 EA patients,
3104 BE patients, and 2182 control subjects. Charac-
teristics of the study sample are shown in Table 1. On
average, BMI was higher among EA (mean, 28.4 kg/m2)
and BE (mean, 28.7 kg/m2) patients than among control
subjects (mean, 27.0 kg/m2). Similarly, EA and BE
patients were more likely than control subjects to be
ever smokers (74.8%, 64.8%, and 59.1%, respectively)
and to report history of recurrent GERD symptoms
(46.9%, 52.9%, and 19.4%, respectively).
Gene-Environment Interactions for EA
For EA, at borderline genome-wide significance, 1
SNP interacted with smoking status and 3 interacted
with recurrent GERD symptoms (P for interactions
ranging from 3.58  10–7 to 1.70  10–7) (Table 2,
Figure 1A and B). At chromosome 2p25.1, rs13429103
(effect allele frequency [EAF] ¼ 15.0%) showed
interaction with smoking status (RNF144A-LOC339788,
P ¼ 2.18  10–7 for interaction). We also observed
borderline statistically significant interactions between
recurrent GERD symptoms and rs12465911 (P ¼ 1.70 
10–7 for interaction), rs2341926 (P ¼ 1.83  10–7 for
interaction), and rs13396805 (P ¼ 3.58  10–7 for
interaction) at chromosome 2q23.3 (RND3-RBM43).
These 3 SNPs are in high linkage disequilibrium (all
r2 > 0.9) as indicated in Figure 1B. Additional suggestive
Table 1. Characteristics of the Study Population
Characteristic
Control Subjects
n ¼ 2182
EA
n ¼ 2284
Control Subjects vs EA
P valuea
BE
n ¼ 3104
Control Subjects vs BE
P Valuea
Age, y 61.7  11.1 65.1  10.3 <.001 62.9  12.1 <.001
Sex <.001 .008
Male 1715 (78.6) 1990 (87.1) 2343 (75.5)
Female 467 (21.4) 294 (12.9) 761 (24.5)
Body mass index, kg/m2 <.001 <.001
Mean 27.0  4.7 28.4  5.2 28.7  5.1
<25 786 (36.3) 245 (24.6) 608 (20.7)
25–29.99 944 (43.5) 455 (45.8) 1191 (42.8)
30 436 (20.2) 296 (29.6) 935 (36.5)
Missing 16 1288 370
Smoking status <.001 <.001
Never 888 (40.9) 568 (25.2) 1081 (35.2)
Ever 1282 (59.1) 1686 (74.8) 1994 (64.8)
Missing 12 30 29
Cumulative smoking
history, pack-yearsb
.43 .001
Mean 32.8  27.9 33.6  26.4 29.4  24.8
Recurrent GERD symptoms <.001 <.001
No 1446 (80.6) 965 (53.1) 1058 (47.1)
Yes 348 (19.4) 854 (46.9) 1186 (52.9)
Missing 388 465 860
NOTE. Values are mean  SD or n (%).
BE, Barrett’s esophagus; EA, esophageal adenocarcinoma; GERD, gastroesophageal reflux disease.
aP value from chi-square tests for categorical variables and Student’s t test for continuous variables. Missing categories were excluded from comparison tests.
bAmong ever smokers.
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10–6 for interaction) are shown in Supplemental Table 1.
In analyses stratified by genotype (Table 3),
compared with never smoking, ever smoking was asso-
ciated with nearly a 12-fold higher risk of EA among
individuals with rs13429103-AA genotype (odds ratio
[OR], 11.82; 95% confidence interval [CI], 4.03–34.67).
In contrast, among individuals with rs13429103-GG ge-
notype, ever smoking conferred only 1.6-fold higher risk
of EA (OR, 1.59; 95% CI, 1.36–1.85). Similarly, the risk
for EA associated with recurrent GERD symptoms was
higher in individuals with rs12465911-AA genotype (OR,
13.12; 95% CI, 6.21–27.73) than among individuals withTable 2.Gene-Environment Interactions With EA or BE With a
Outcome Exposure SNP Chr Pos
EA
Smoking status rs13429103 2p25.1 751
Recurrent GERD symptoms rs12465911 2q23.3 15178
Recurrent GERD symptoms rs2341926 2q23.3 15178
Recurrent GERD symptoms rs13396805 2q23.3 15182
BE
BMI (continuous) rs491603 1p34.3 3653
Pack-years of smoking rs11631094 15q14 3462
BE, Barrett’s esophagus; BMI, body mass index; EA, esophageal adenocarcinoma
ratio; SNP, single nucleotide polymorphism.rs12465911-GG genotype (OR, 2.80; 95% CI, 2.29–3.41).
Additional stratified analyses for risk of EA are shown in
Table 3 and Supplemental Table 2.Gene-Environment Interactions for BE
For BE, at chromosome 1p34.3, we observed an
interaction between rs491603 (EAF ¼ 16.5%) and
BMI (EIF2C3-LOC100128093, P ¼ 4.44  10–7 for
interaction) (Table 2, Figure 1C). At chromosome
15p14, rs11631094 (EAF ¼ 28.7%) showed interac-
tion with pack-years of smoking exposure (SLC12A6,P Value for Interaction <5.0  10–7
ition Gene
Effect/
Other EAF OR P
7231 RNF144A-LOC339788 A/G 0.15 2.04 2.18  10–7
5742 RND3-RBM43 A/G 0.26 2.03 1.70  10–7
3928 RND3-RBM43 C/T 0.26 2.02 1.83  10–7
1512 RND3-RBM43 A/G 0.26 1.99 3.58  10–7
2316 EIF2C3-LOC100128093 A/G 0.16 1.08 4.44  10–7
4438 SLC12A6 A/C 0.29 0.99 2.82  10–7
; EAF, effect allele frequency; GERD, gastroesophageal reflux disease; OR, odds
Figure 1. Regional association plots for genotyped single nucleotide polymorphisms (SNPs) showing P values for interaction
for (A) smoking status and (B) recurrent gastroesophageal reflux disease symptoms in esophageal adenocarcinoma and (C)
body mass index and (D) pack-years of smoking exposure in Barrett’s esophagus. The SNPs in Table 2 are shown as a solid
purple diamond, except in panel B where rs2341926 and rs13396805 are shown as circles near rs12465911. The color scheme
indicates linkage disequilibrium between the SNP shown with a solid purple diamond and other SNPs in the region using the r2
value calculated from the 1000 Genomes Project. The y axis is the log10 interaction P value computed from 5388 cases
(3104 Barrett’s esophagus, 2284 esophageal adenocarcinoma) and 2182 control subjects. The recombination rate from CEU
HapMap data (right-side y axis) is shown in light blue. (A) Chromosome 2p25.1; (B) chromosome 2q23.3 region; (C) chro-
mosome 1p34.3 region; (D) chromosome 15q14 region.
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Additional suggestive significant interactions (where
P < 1.0  10–6 for interaction) for BE with pack-years
of smoking exposure at chromosomes 12q23.1,
16p12.3, and 17q12 are presented in Supplemental
Table 1.
Stratified analyses by genotype showed that the risk
for BE associated with obesity (BMI 30 kg/m2) was
elevated by over 200% among individuals with
rs491603-AA genotype (vs BMI <25 kg/m2; OR, 3.30;
95% CI, 1.90–5.73) but only by approximately
50% among individuals with rs491603-GG genotype
(vs BMI <25 kg/m2; OR, 1.52; 95% CI, 1.38–1.67).
Additional stratified analyses of gene-environment
interactions for BE are shown in Table 3 and
Supplemental Table 2.Cross-Examination of Discovered
Gene-Environment Interactions
For each SNP in Table 2 and Supplemental Table 1
that had a borderline significant genome-wide interac-
tion in either EA or BE, we examined the equivalent
gene-environment interaction in BE and EA, respec-
tively (Supplemental Table 3). For all SNPs discovered
in EA, we observed nominal levels of significance (P
value for interaction <.05) and ORs in the same direc-
tion but somewhat attenuated in BE. For SNPs discov-
ered in BE, only half had P value for interaction <.05 in
EA, although all had similar ORs to those in BE. Although
obesity and GERD are correlated, none of the SNPs with
P value for interaction <1.0  10–6 with GERD had
comparable ORs or P values when testing for interaction
Table 3. Risk of EA and BE in Association With Obesity, Smoking History and Recurrent GERD Symptoms, Stratified by
Genotype for SNPs in Table 2
Outcome
Environmental
Exposure SNP Genotype
Cases/Control
Subjects OR 95% CI
P
Valuea
EA
Ever smoker vs never smoker (ref) rs13429103 GG 1617/1572 1.59 1.36–1.85 <.001
GA 589/554 2.91 2.23–3.81 <.001
AA 48/44 11.82 4.03–34.67 <.001
Recurrent GERD symptoms vs
nonrecurrent GERD symptoms (ref)
rs12465911 GG 1206/1196 2.80 2.29–3.41 <.001
GA 885/823 5.32 4.10–6.90 <.001
AA 163/151 13.12 6.21–27.73 <.001
Recurrent GERD symptoms vs
nonrecurrent GERD symptoms (ref)
rs2341926 TT 975/985 2.80 2.30–3.42 <.001
TC 724/681 5.30 4.08–6.88 <.001
CC 120/128 13.12 6.21–27.73 <.001
Recurrent GERD symptoms vs
nonrecurrent GERD symptoms (ref)
rs13396805 GG 998/1005 2.85 2.34–3.48 <.001
GA 701/662 5.23 4.02–6.81 <.001
AA 120/127 12.73 6.12–26.49 <.001
BE
BMI 30 kg/m2 vs BMI <25 kg/m2 (ref) rs491603 GG 1306/1137 1.52 1.38–1.67 <.001
GA 438/518 2.11 1.80–2.47 <.001
AA 42/64 3.30 1.90–5.73 <.001
15 pack-years vs <15 pack-years (ref) rs11631094 CC 729/618 1.02 0.81–1.30 .846
CA 555/540 0.65 0.50–0.84 .001
AA 115/106 0.52 0.28–0.95 .033
BE, Barrett’s esophagus; BMI, body mass index; CI, confidence interval; EA, esophageal adenocarcinoma; GERD, gastroesophageal reflux disease; OR, odds
ratio; SNP, single nucleotide polymorphism.
aP values from logistic regression analysis adjusted for age and sex.
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tested for GERD.
Discussion
To our knowledge, this is the first genome-wide
gene-environment interaction study of EA and its pre-
cursor, BE. Although no gene-environment interactions
reached genome-wide significance (ie, P < 5.0  10–8 for
interaction), several borderline significant interactions
were indicated between SNPs and known risk factors for
EA and BE – BMI, smoking, and GERD symptoms.
A number of studies have pursued candidate-based
gene-environment analyses of EA, and reported in-
teractions between BMI, smoking or GERD symptoms
and selected SNPs in genes related to detoxification,
angiogenesis, DNA repair, apoptosis, and extracellular
matrix degradation.24–31 This body of work helped to
establish the notion that the level of disease risk asso-
ciated with GERD symptoms, in particular, may vary
according to inherited genetic variation. All of these
studies, however, were conducted in small samples
(<350 cases) and were not replicated in independent
populations. While direct comparison of our own results
and these past findings is complicated by less-than-
complete overlap of genotyped SNPs between studies,
we did not find evidence in support of interactions
among BMI, smoking, or GERD symptoms and anyassessed variants in previously-implicated genes: GSTM1,
GSTT1, VEGF, MGMT, EGF, IL1B, PERP, PIK3CA,
TNFRSF1A, CASP7, TP53BP1, BCL2, HIF1AN, PDGRFA,
VEGFR1, or MMP1 (Supplemental Table 4). It remains
possible that nominal evidence for some of these asso-
ciations may not have survived stringent correction for
multiple comparisons, and larger samples are needed for
true signals to reach significance. Alternatively, previ-
ously reported interactions may simply reflect chance
findings in small samples because they did not validate
in our large study population.
This study has several strengths. First, the pooled
dataset including relatively large numbers of cases and
control subjects provided us with a rare opportunity to
perform, in parallel, genome-wide gene-environment
interaction analyses for EA and its precursor lesion, BE.
Past candidate-based gene-environment interaction
studies of EA have focused on small numbers of genes
selected according to biological plausibility, and collec-
tively these reports sampled only a small fraction of
the total SNPs presently analyzed (N ¼ 993,501). Such
preconceived “gene-centric” SNP selection methods fail
to capture the large fraction of noncoding intergenic
variations that have been linked to altered risk for these
2 conditions, and also artificially restricts the “genic”
search space based on limited mechanistic knowledge,
a limitation that is overcome by an unbiased compre-
hensive genome-wide gene-environment interaction
1604 Dong et al Clinical Gastroenterology and Hepatology Vol. 16, No. 10assessment. Second, our study draws on genetic and
epidemiologic data from a recent consortium-based
GWAS of EA/BE,20 which is the largest of its kind. This
sizable study sample afforded greater power to detect
gene-environment interactions than in any previous
study. Third, all genotyping from this GWAS was con-
ducted on a single platform and in a single laboratory,
and subjected to stringent quality-control procedures.
Most GWAS analyses test only an additive model because
an additive model has reasonable power to detect both
additive and dominant effects and the 2 models yield
similar results and many GWAS analyses, including
ours, are underpowered to detect recessive effects.
Nevertheless, for completeness we also tested a domi-
nant model for the 16 SNPs with a P value for interaction
<1.0  10–6 (Table 2 and Supplemental Table 1), and
found slightly attenuated results of the ORs for some
gene-environment interactions (data not shown).
Our study also has some limitations. First, our ability
to detect true gene-environment interactions might have
been limited by the manner in which the environmental
(exposure) variables were measured and harmonized.
For example, recall bias is a possibility during retro-
spective reporting of the exposures in the parent case-
control studies. However, respondents were unaware of
their genotype status at the time of the interviews,
mitigating the impact of any possible recall bias in our
interaction analyses. Similarly, while considerable care
was taken during data harmonization, as described in a
series of recent pooled analyses,10,11 some potential for
measurement error of the exposures examined is
possible. However, given that case-control status was not
considered during this process, any errors from harmo-
nization would be nondifferential, resulting in attenua-
tion of the resulting ORs. Second, central obesity
(eg, waist-to-hip ratio) has been found to be more
strongly associated with the risk of BE than BMI;
however, as waist and hip measurements were not
collected in the majority of the included studies, we were
unable to examine for interactions with central obesity.
Third, despite the comprehensive nature of the genome-
wide analysis, we were nonetheless limited to examining
common genetic variation (MAF >2%) represented on
the Illumina Omni1M Quad GWAS platform employed.
Further large-scale studies based on whole-exome or
whole-genome sequencing would be required to identify
additional gene-environment interactions with rare
variants, and more precisely map the reported associa-
tions. Finally, our study results should be considered as
discovery findings, worthy of independent replication.
None of the interactions studied reached genome-wide
significance (ie, P < 5.0  10–8 for interaction). This
may be because there are truly no gene-environment
interactions or it may be that power was still limited to
detect modest or weak interactions despite our large
sample size. In our analyses of 2284 EA patients, 3104
BE patients, and 2182 control subjects, we were
adequately powered to detect interactions with aninteraction OR in the range of 1.98–2.52 for MAF in the
observed range (0.11–0.43), assuming a main effect of
1.08 for log-additive SNPs, a main effect of 1.90 for
binary risk factors, and an a of 5.0  10–8. Given the
large worldwide consortia sample of patients partici-
pating in this work, few additional studies of EA and BE
patients are currently available and have data for repli-
cation; thus, such work may require additional time for
study patients to accrue.
In conclusion, our report describes the first genome-
wide gene-environment interaction analysis for EA and
BE. These findings provide evidence that the magnitude
of disease risk associated with BMI, smoking, and GERD
symptoms may differ according to germline genetics,
and suggest the potential utility of combing epidemio-
logic exposure data with selected genotyping for
comprehensive risk assessment in patients susceptible
to EA or BE. Pending validation of the observed
interactions in independent study populations, further
analyses will be required to investigate the biological
basis for differential disease risk associated with the
risk factors investigated in the presence of these
variants.
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Supplemental Table 1.Gene-Environment Interactions With EA or BE With a P Value for Interaction <1.0  10–6
Outcome Exposure SNP Chr Position Gene
Effect/
Other EAF OR P Value
EA
Smoking status rs2434584 5q11.2 57566073 ACTBL2-PLK2 C/T 0.08 2.52 7.44  10–7
Smoking status rs40210 5q11.2 57619964 ACTBL2-PLK2 A/G 0.08 2.46 8.82  10–7
Pack-years of smoking rs17002540 Xq27.1 139946061 CDR1-SPANXB2 T/C 0.19 0.99 5.92  10–7
Recurrent GERD symptoms rs2971030 7p21.3 10006341 LOC340268 G/A 0.42 1.77 6.02  10–7
Recurrent GERD symptoms rs7141987 14q32.31 101492224 SNORD114-31-
LOC100130814
G/A 0.42 1.77 7.11  10–7
Recurrent GERD symptoms rs2971028 7p21.3 10007255 LOC340268 A/G 0.40 1.76 8.56  10–7
BE
Pack-years of smoking rs9668109 12q23.1 99011272 IKIP A/G 0.09 0.98 6.31  10–7
Pack-years of smoking rs1548445 16p12.3 19691583 C16orf62 G/A 0.06 1.02 8.21  10–7
Pack-years of smoking rs2671828 17q12 33731764 SLFN11-LOC729839 A/G 0.43 0.99 9.54  10–7
Pack-years of smoking rs10507102 12q23.1 98990871 SLC25A3 A/G 0.09 0.98 9.91  10–7
BE, Barrett’s esophagus; BMI, body mass index; EA, esophageal adenocarcinoma; EAF, effect allele frequency; GERD, gastroesophageal reflux disease; OR, odds
ratio; SNP, single nucleotide polymorphism.
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Supplemental Table 2. Risk of EA and BE in Association With Smoking History and GERD Symptoms, Stratified by Genotype
for SNPs in Supplemental Table 1
Outcome
Environmental
Exposure SNP Genotype
Cases/Control
Subjects OR 95% CI
P
Valuea
EA
Ever smoker vs never smoker (ref) rs2434584 TT 1907/1826 1.67 1.45–1.93 <.001
CT 342/328 4.33 3.00–6.24 <.001
CC 5/15 NA - -
Ever smoker vs never smoker (ref) rs40210 GG 1903/1821 1.67 1.45–1.92 <.001
GA 344/332 4.24 2.96–6.06 <.001
AA 6/16 NA - -
15 pack-years vs <15 pack-years (ref) rs17002540 CC 1053/1003 1.36 1.12–1.66 .002
CT 48/55 0.78 0.33–1.86 .579
TT 218/206 0.63 0.39–1.00 .052
Recurrent GERD symptoms vs
nonrecurrent GERD symptoms (ref)
rs2971030 AA 599/603 2.68 2.08–3.44 <.001
GA 908/895 3.81 3.06–4.75 <.001
GG 309/293 9.44 6.17–14.45 <.001
Recurrent GERD symptoms vs
nonrecurrent GERD symptoms (ref)
rs7141987 AA 591/590 2.69 2.08–3.49 <.001
GA 908/887 3.74 3.02–4.64 <.001
GG 319/317 9.32 6.04–14.36 <.001
Recurrent GERD symptoms vs
nonrecurrent GERD symptoms (ref)
rs2971028 GG 625/635 2.70 2.11–3.45 <.001
GA 900/890 3.87 3.10–4.82 <.001
AA 294/268 9.58 6.17–14.88 <.001
BE
15 pack-years vs <15 pack-years (ref) rs9668109 GG 1167/1058 0.92 0.77–1.11 .390
GA 221/201 0.38 0.25–0.60 <.001
AA 11/5 0.33 0.02–5.64 .443
15 pack-years vs <15 pack-years (ref) rs1548445 AA 1223/1097 0.76 0.63–0.91 .002
GA 170/164 1.11 0.68–1.80 .675
GG 6/3 NA - -
15 pack-years vs <15 pack-years (ref) rs2671828 GG 457/423 0.93 0.70–1.23 .595
GA 688/588 0.84 0.66–1.07 .163
AA 246/250 0.54 0.36–0.80 .002
15 pack-years vs <15 pack-years (ref) rs10507102 GG 1166/1058 0.93 0.77–1.11 .409
GA 222/200 0.38 0.24–0.59 <.001
AA 11/5 0.33 0.02–5.64 .443
BE, Barrett’s esophagus; BMI, body mass index; EA, esophageal adenocarcinoma; EAF, effect allele frequency; GERD, gastroesophageal reflux disease; SNP,
single nucleotide polymorphism.
aP values from logistic regression analysis adjusted for age and sex.
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Supplemental Table 3. Comparison of Gene-Environment Interactions in BE and EA for SNPs With P Value for Interaction
<1.0  10–6 on the Outcomes
Exposure SNP Chr Position Gene
Effect/
Other
BE EA
OR P OR P
G  E hits for EA
Smoking status rs13429103 2p25.1 7517231 RNF144A-LOC339788 A/G 1.40 3.51  10–3 2.04 2.18  10–7
Smoking status rs2434584 5q11.2 57566073 ACTBL2-PLK2 C/T 1.56 3.90  10–3 2.52 7.44  10–7
Smoking status rs40210 5q11.2 57619964 ACTBL2-PLK2 A/G 1.54 4.94  10–3 2.46 8.82  10–7
Pack-years of smoking rs17002540 Xq27.1 139946061 CDR1-SPANXB2 T/C 0.99 4.83  10–3 0.99 5.92  10–7
Recurrent GERD symptoms rs12465911 2q23.3 151785742 RND3-RBM43 A/G 1.66 6.09  10–5 2.03 1.70  10–7
Recurrent GERD symptoms rs2341926 2q23.3 151783928 RND3-RBM43 C/T 1.65 7.38  10–5 2.02 1.83  10–7
Recurrent GERD symptoms rs13396805 2q23.3 151821512 RND3-RBM43 A/G 1.59 2.80  10–4 1.99 3.58  10–7
Recurrent GERD symptoms rs2971030 7p21.3 10006341 LOC340268 G/A 1.36 5.03  10–3 1.77 6.02  10–7
Recurrent GERD symptoms rs7141987 14q32.31 101492224 SNORD114-31-
LOC100130814
G/A 1.29 1.40  10–2 1.77 7.11  10–7
Recurrent GERD symptoms rs2971028 7p21.3 10007255 LOC340268 A/G 1.35 6.10  10–3 1.76 8.56  10–7
G  E hits for BE
BMI (continuous) rs491603 1p34.3 36532316 EIF2C3-LOC100128093 A/G 1.08 4.44  10–7 1.04 1.83  10–2
Pack-years of smoking rs11631094 15q14 34624438 SLC12A6 A/C 0.99 2.82  10–7 1.00 0.125
Pack-years of smoking rs9668109 12q23.1 99011272 IKIP A/G 0.98 6.31  10–7 0.99 9.74  10–3
Pack-years of smoking rs1548445 16p12.3 19691583 C16orf62 G/A 1.02 8.21  10–7 1.01 9.70  10–2
Pack-years of smoking rs2671828 17q12 33731764 SLFN11-LOC729839 A/G 0.99 9.54  10–7 1.00 6.13  10–2
Pack-years of smoking rs10507102 12q23.1 98990871 SLC25A3 A/G 0.98 9.91  10–7 0.99 6.93  10–3
BE, Barrett’s esophagus; BMI, body mass index; EA, esophageal adenocarcinoma; EAF, effect allele frequency; G  E, gene-environment; GERD, gastro-
esophageal reflux disease; OR, odds ratio; SNP, single nucleotide polymorphism.
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Supplemental Table 4. Associations of Previously Reported Gene-Environment Interactions With Esophageal
Adenocarcinoma in Our Study Population
Original Publication Current Study
Author SNP Exposure P Value
Directly Genotyped
or High-LD SNP P Value
Casson et al, 200624 NA - - - -
Zhai et al, 200825 rs833061 Smoking .03 rs833070 .068
Doecke et al, 200826 rs12269324 GERD symptoms - Direct .979
rs12268840 GERD symptoms - Direct .714
Cheung et al, 200927 rs4444903 GERD symptoms <.001a Direct .240
Zhai et al, 201228 rs1143634 GERD symptoms .008 Direct .398
rs1052486 BMI þ Smoking - - -
rs1052486 BMI - Direct .423
rs1052486 Smoking - Direct .532
Wu et al, 201129 rs648802 GERD symptoms .02 Direct .838
rs4855094 GERD symptoms .04 Direct .872
rs7644468 GERD symptoms .04 - -
rs4149579 GERD symptoms .04 - -
rs560191 Smoking .02 Direct .331
rs7907519 Smoking .04 rs11196449 .868
rs12454712 Smoking .04 Direct .435
Zhai et al, 201230 rs2295778 GERD symptoms .0005 rs12780796 .654
rs13337626 GERD symptoms .0067 rs34197769 .315
rs2295778 Smoking .004 - -
rs2296188 Smoking .014 Direct .905
rs2114039 BMI .0026 Direct .228
rs2296188 BMI .0023 Direct .452
rs11941492 BMI .013 Direct NAb
rs17708574 BMI .013 Direct .316
rs7324547 BMI .008 - -
rs17619601 BMI .016 - -
rs17625898 BMI .023 - -
Cheung et al, 201231 rs1799750 GERD symptoms .002 - -
rs3025058 GERD symptoms .04 - -
BMI, body mass index; GERD, gastroesophageal reflux disease; LD, linkage disequilibrium; SNP, single nucleotide polymorphism.
aTwo-way interaction.
bOn array but quality control failure. We were unable to validate all SNPs as some were biallelic or we failed to identify a high LD SNP (r2 < 0.70).
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